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Abstract
The main cause of death in systemic sclerosis is interstitial lung disease, followed by pul-
monary hypertension (PH). Pulmonary hypertension is the result of microvasculopathy 
which is caused by a disrupted healing process of endothelin damage and is featured by 
vasoconstriction, proliferation of arterial wall, inflammation, and fibrosis. Reclassification 
of pulmonary hypertension has led to five distinctive groups. In systemic sclerosis, 
patients may suffer from pulmonary artery hypertension (PAH, group 1), pulmonary 
hypertension due to interstitial lung disease (group 3), cardiac disease (group 2), and/
or thromboembolic pulmonary hypertension (group 4). Patients endure declining per-
formance during exercise, but symptoms may be variable and nonspecific. Diagnosis is 
made by right heart catheterization. To select patients for this invasive procedure, several 
screening tools are discussed, including N-terminal pro-brain natriuretic peptide levels, 
uric acid levels, spirometry and diffusing capacity for carbon monoxide (DCLO), echo-
cardiography (ECG), and the DETECT algorithm. Depending on features such as disease 
duration, presence of anti-centromere antibodies, and DCLO, three different flow charts 
for screening are presented. Based on pathophysiology, several medical treatments have 
been developed like prostanoids, endothelin receptor antagonists, phosphodiesterase-5 
inhibitors, and stimulation of the nitric oxide pathway. Combination therapy as well as 
lung transplantation and supportive therapy is discussed.
Keywords: systemic sclerosis, pulmonary hypertension, DETECT algorithm, pharma-
ceutical treatment (prostanoids, endothelin receptor antagonists, phosphodiesterase-5 
inhibitors, nitric oxide pathway)
1. Pulmonary hypertension
Pulmonary hypertension (PH) is a progressive disease characterized by an elevated pulmo-
nary arterial pressure and pulmonary vascular resistance. As a consequence of the elevated 
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pulmonary arterial pressure, patients are at risk of right ventricular failure and death. PH is 
classified in five distinctive groups with similar pathophysiology, patient characteristics, and 
treatment options. It can occur as a complication in patients with systemic sclerosis, and as 
such, it is the second main cause of death after pulmonary fibrosis in patients with systemic 
sclerosis. The estimated 3-year survival among patients with PH associated with systemic 
sclerosis is approximately 55% compared with 95% in those patients without PH [1]. The 
diagnosis of pulmonary arterial hypertension is defined at right heart catheterization (RHC) 
by a mean pulmonary arterial pressure (mPAP) of ≥ 25 mmHg. RHC should be performed in 
all patients in whom PH is suspected. Early diagnosis and, subsequently, treatment of PH are 
of utmost importance since they improves survival rates.
1.1. Epidemiology
In patients with systemic sclerosis, approximately 10% develop pulmonary arterial hyper-
tension as a complication of the disease [2, 3]. Prior to the availability of disease-specific PH 
therapies, the median survival for PH in patients with systemic sclerosis was 1 year following 
diagnosis [4]. A meta-analysis accomplished in 2013 with the inclusion of 22 studies repre-
senting 2244 patients with systemic sclerosis-associated PH showed that the current pooled 
survival rates after 1,2, and 3 years are respectively 81% (95% confidence interval [95% CI] 
79–84%), 64% (95% CI 59–69%), and 52% (95% CI 47–58%) [5]. To note, the prognosis of PH 
associated with systemic sclerosis is substantially worse than patients with idiopathic pul-
monary artery hypertension (PAH) [6]. PH is generally considered a late complication of the 
disease, but in fact, it can occur at any time following the diagnosis. In a study from Hachulla 
et al. [7], PH was diagnosed 6.3 ± 6.6 years after the first non-Raynaud symptom of systemic 
sclerosis. It was also shown that patients with early-onset PH were older at systemic sclerosis 
diagnosis than patients with late-onset PH (mean age, 58.0 ± 12.5 vs 46.6 ± 12.9 years), and 
that, early-onset PH was more severe than late-onset PH, with a lower cardiac index and 
greater total pulmonary resistance. Despite these differences, the mortality however was com-
parable between the early-onset and late-onset PH groups. In general, patients with limited 
cutaneous systemic sclerosis are considered to be at greater risk of PH than patients with 
diffuse cutaneous systemic sclerosis [8, 9]. In these studies, however, the diagnosis of PH was 
not always based on right heart catheterization but by Doppler echocardiography. In a retro-
spective cohort analysis from Nihtyanova et al. [10], it was found that the prevalence of RHC 
confirmed PH was similar in diffuse cutaneous systemic sclerosis (7%) and limited cutaneous 
systemic sclerosis (8%).
1.2. Classification of pulmonary hypertension
The classification of PH went through a series of changes since the first classification was 
proposed in 1973 by the World Health Organization (WHO) [11]. This first meeting was 
organized due to the epidemic of the aminorex-induced PAH. Before this date, there 
was little knowledge of PH, and there were no effective drugs available resulting in a sur-
vival prognosis of several years. Despite the fact that PH was an orphan disease, significant 
interest from scientists with collaborative effort from the pharmaceutical industry resulted 
in studies focusing on pathophysiology, molecular biology, epidemiology, and clinical trials. 
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Prompted by the attained scientific insights, the second world symposium on PH was held in 
Evian, France. Here, in 1998, the ‘Evian’ classification was proposed which consisted of five 
categories which shared pathophysiology, clinical patient characteristics, and pharmacologi-
cal treatment options [12]. Five years after the Evian conference, the third world symposium 
on PH was held in Venice where several changes were made to the Evian classification. At 
this time, there were already three classes of drugs effective in the treatment of PH (pros-
tanoids, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors), and a 
specific treatment algorithm was proposed [13]. At the fourth world symposium on PH held 
in Dana Point, California, the Evian-Venice classification composition was refined, and a 
few modifications, reflecting new scientific knowledge, were added. The last world sympo-
sium on PH was held in Nice, France, in 2013. At that moment, several worldwide experts 
were divided into 12 task forces, each with a specific topic related to PH [14]. The task force 
responsible for the clinical classification proposed to include the individual categorization of 
the persistent PH of neonates, the addition of congenital diseases in groups 2, 3, and 5, and 
the shifting of PH associated with chronic hemolytic anemia from group 1 to group 5 [15]. 
Table 1 shows the last updated clinical classification of pulmonary hypertension proposed 
in 2015 [16].
In systemic sclerosis, patients may suffer from both pulmonary artery hypertension (PAH, 
group 1) and from pulmonary hypertension due to interstitial lung disease (group 3), cardiac 
disease (group 2), and/or chronic thromboembolic pulmonary hypertension (group 4). The 
diagnosis and evaluation of PH is through a series of testing including pulmonary function 
testing, such as the measurement of DCLO, chest X-ray, high resolution computed  tomog-
raphy (HRCT) scan, ECG, echocardiography, cardio-pulmonary exercise test, and laboratory 
testing, including antinuclear antibodies, and is always confirmed by the gold standard, a 
right heart catheterization.
1.3. Pathophysiology
PH is a hemodynamic abnormality of the pulmonary vasculature most often found in patients 
with heart and lung diseases. PH is also present in approximately 10% of the patients with 
systemic sclerosis [2, 3]. The consensus definition of PH, an mean pulmonary arterial pressure 
(mPAP) of ≥25 mm Hg, originates from the fifth world symposium on PH [17]. The normal 
physiological upper limit for mPAP is considered 20 mm Hg. The significance and prognosis 
is unknown so far in patients with a mildly elevated mPAP, that is a resting mPAP between 
21 and 24 mmHg. In patients with systemic sclerosis for 3 years and 5 years after diagnosis of 
systemic sclerosis, respectively, 18.5% (95% CI 8.3–28.7) and 27.1% (95% CI 13.9–40.3) devel-
oped PH [18]. This implies that these patients should be carefully monitored.
PH may be due to abnormalities confined to the pulmonary arterial blood vessels (pre-capil-
lary PH), to elevation of pulmonary venous pressure (post-capillary PH), to elevated resistance 
in the pulmonary capillary bed, to elevated cardiac output, or to a combination of these factors. 
Pre-capillary pulmonary hypertension is also called pulmonary arterial hypertension (PAH) 
and is considered one of the major clinical PH subtypes. In PAH, the hemodynamic hallmark 
states a normal pulmonary venous pressure measured as a pulmonary capillary wedge pres-
sure (PCWP) of 15 mmHg or less and a high mPAP. As a consequence, the transpulmonary 
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1. Pulmonary arterial hypertension
 1.1. Idiopathic PAH
 1.2 Heritable PAH
  1.2.1. BMPR2
  1.2.2. ALK1, ENG, SMAD9, CAV1, KCNK3
  1.2.3. Unknown
 1.3. Drug- and toxin-induced
 1.4. Associated with
  1.4.1. Connective tissue disease
  1.4.2. HIV infection
  1.4.3. Portal hypertension
  1.4.4. Congenital heart disease
  1.4.5. Schistosomiasis
  1.4.6. Chronic hemolytic anemia
 1.5. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)
 1.5.1. Idiopathic
 1.5.2. Heritable
   1.5.2.1. EIF2AK mutation
   1.5.2.2. Other mutations
 1.5.3. Drugs, toxins, and radiation induced
 1.5.4. Associated with:
   1.5.4.1. Connective tissue disease
   1.5.4.2. HIV infection
 1.6. Persistent pulmonary hypertension of the newborn (PPHN)
2. Pulmonary hypertension due to left heart disease
 2.1. Left ventricular systolic dysfunction
 2.2. Left ventricular diastolic dysfunction
 2.3. Valvular disease
 2.4. Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies
 2.5. Congenital/acquired pulmonary veins stenosis
3. Pulmonary hypertension owing to lung disease and/or hypoxia
 3.1. Chronic obstructive pulmonary disease
 3.2. Interstitial lung disease
 3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern
 3.4. Sleep-disordered breathing
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gradient is elevated as is the pulmonary vascular resistance. In post-capillary PH, also called 
pulmonary venous hypertension, the elevated PH is a consequence of an increased resistance 
to blood flow anywhere downstream from the pulmonary capillaries such as the pulmonary 
veins, left heart of even the systemic vasculature. This results in an elevated PCWP and most 
often normal transpulmonary gradient. The presence of solely a high cardiac output rarely 
results in marked PH since a healthy pulmonary vasculature is highly compliant. So the pres-
ence of PH in a situation with high cardiac output always suggests a pulmonary vascular 
defect.
In patients with systemic sclerosis, each of the PH subtypes may be present to different 
degrees. Figure 1 provides a schematic view of the pulmonary vasculature and shows the 
anatomical location of the clinical subtypes of PH in patients with systemic sclerosis.
It is important to quantify each subtype in a patient, since it provides a prognosis for pos-
sible treatment effects. For example, PH associated with interstitial lung disease (ILD) has a 
worse prognosis compared to PAH in patients with systemic sclerosis [19–21]. A high mPAP 
in patients with systemic sclerosis can be due to proliferative pulmonary vasculopathy (PAH) 
featured by pulmonary artery vasoconstriction, proliferation of adventitia and intima wall, 
inflammation, and, ultimately, fibrosis. The PH may also be a consequence of the associ-
ated lung fibrosis due to prominent parenchymal destruction. The differentiation between 
PAH and pulmonary fibrosis-associated PH is sometimes difficult. In general, lung volumes 
 3.5. Alveolar hypoventilation disorders
 3.6. Chronic exposure to high altitude
 3.7. Developmental abnormalities
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
 4.1. Chronic thromboembolic pulmonary hypertension
 4.2. Other pulmonary artery obstructions
  4.2.1. Angiosarcoma
  4.2.2. Other intravascular tumors
  4.2.3. Arteritis
  4.2.4. Congenital pulmonary arteries stenosis
  4.2.5. Parasites (hydatidosis)
5. Pulmonary hypertension with unclear multifactorial mechanisms
 5.1. Hematological disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy
 5.2. Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis, neurofibromatosis
 5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders
 5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental PH
Table 1. Updated clinical classification of pulmonary hypertension in 2015.
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(forced vital capacity (FVC) and/or total lung capacity (TLC)) below 60% of the predicted 
value indicate that PH is more likely to be associated with pulmonary fibrosis. When lung 
volumes (FVC and/or TLC) are above 70% of the predicted value, the PH is considered more 
likely to be due to PAH. For lung volumes between 60–70% of the predicted value, the cause 
is uncertain. Another cause of a high mPAP in patients with systemic sclerosis is pulmonary 
veno-occlusive disease (PVOD) [22]. This is thought to be the result of a more diffuse nature 
of the vascular lesions associated with systemic sclerosis and is located in the small venules 
of the vascular bed. Patients with PVOD often have more severe hypoxemia and a severe 
decrease in pulmonary diffusion capacity for carbon monoxide (DCLO). Indications for 
PVOD are typical radiological signs (lymph node enlargement, centrolobular ground glass 
opacities, and septal lines [23], hemoptysis, and severe hypoxemia). The diagnosis of PVOD 
is important since it may be harmful to prescribe pulmonary vasodilators since these vasodi-
lators increase the risk for developing pulmonary edema. Also, post-capillary PH is seen in 
patients with systemic sclerosis, merely as a result of left ventricle diastolic dysfunction due 
to cardiomyopathy as indicated by an elevated PCWP > 15 mmHg [24, 25].
2. Diagnosis of pulmonary hypertension
2.1. Physical signs and symptoms
The first signs and symptoms of pulmonary hypertension are generally vague and nonspe-
cific. Patients experience tiredness, fatigue, and shortness of breath when performing physi-
cal exercise or activities of daily living such as climbing stairs. These symptoms are often 
ascribed to having a low physical fitness. More severe symptoms such as feeling light headed 
during exercise, angina, syncope, and/or ankle edema only occur after extensive pulmonary 
vasculopathy have been developed. Also with physical examination, there are no specific 
abnormalities detected in patients with mild PH. Only when there is extensive pulmonary 
Figure 1. A schematic view of the pulmonary vasculature. RA: right atrium, RV: right ventricle, PAH: pulmonary arterial 
hypertension, ILD: interstitial lung disease, PVOD: pulmonary veno-occlusive disease, LV: left ventricle, LAP: left atrial 
pressure, and A: aorta.
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vasculopathy resulting in right heart failure, there may be physical signs including a loud 
P2 cardiac sound, a right ventricle third sound, a murmur of tricuspid regurgitation, raised 
central venous pressure, and other signs of right heart failure such as an enlarged liver and 
ankle edema. The lack of symptoms until the PH is already advanced often results in a strik-
ing patient and doctor’s delay for diagnosis and consecutively effective treatment. As a con-
sequence, the majority of patients at diagnosis are in functional New York Heart Association/
World Health Organization (NYHA/WHO) class III or IV (Table 2) [2, 26]. This is extraordi-
narily unfortunate since the prognosis is much worse in NYHA/WHO functional class III–IV 
compared to class I–II [27].
2.2. Screening for pulmonary hypertension
Patients with systemic sclerosis are at risk of developing pulmonary hypertension. Since the 
first signs and symptoms of PH are nonspecific and the prognosis of patients diagnosed and 
treated in less advanced stages is better than those diagnosed late, in recent years, several 
screening programs have been developed to detect PH as early as possible. Depending on fea-
tures such as disease duration, results from pulmonary function tests, and echocardiography, 
three different flow charts will be discussed.
In all newly diagnosed patients with systemic sclerosis, it is advised to perform a yearly 
screening for PH. After performing a thorough history and physical examination, patients 
should undergo a series of tests including pulmonary function test (including FVC, TLC, 
and diffusion capacity for carbon monoxide (DCLO)), chest X-ray, HRCT scan, ECG, echo-
cardiography, and laboratory testing including antinuclear antibodies and N-terminal pro-
Brain Natriuretic Peptide (N-terminal pro-BNP). Since the gold standard for diagnosing PH 
is right heart catheterization (RHC) an algorithm is used to indicate which patients should 
subsequently undergo the invasive procedure of an RHC [2, 28]. An RHC is recommended 
for those patients with an FVC/DCLO higher than 1.6 and/or DCLO below 60% of predicted 
values for those who experience shortness of breath or have a N-terminal pro-BNP more 
than twice the upper limit of normal (Figure 2A). For the patients where the echocardiog-
raphy shows right atrial or right ventricle enlargement, a tricuspid regurgitant jet velocity 
(TRJ) higher than 2.8 m/s or a TRJ between 2.5 and 2.8 m/s with shortness of breath, it is also 
strongly advised to perform an RHC (Figure 2B).
For those patients with systemic sclerosis and a disease duration of more than 3 years and a 
pulmonary DCLO below 60% of the predicted value, the DETECT algorithm as described in 
Class I: PH but no symptoms and no limitations in ordinary physical activity, for example, no shortness of breath 
when walking, climbing the stairs, and so on.
Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitations during ordinary activity.
Class III: Marked limitations in activity due to symptoms even during a less-than-ordinary activity, for example, 
walking short distances (20–100 m). Comfortable only at rest.
Class IV: Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.
Table 2. New York Heart Association/WHO functional class.
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Figure 3 is advised to be conducted yearly [29]. The objective of the DETECT study was to 
develop the first evidence-based detection algorithm for systemic sclerosis–associated PH. 
This algorithm would minimize the number of missed PH diagnoses while optimizing the use 
of diagnostic RHC by determining those patients with systemic sclerosis that will not benefit 
from catheterization. In the first step of the DETECT algorithm, six relatively simple assess-
ments are used to determine which patients should be referred for an echocardiography. 
These assessments are a percentage of predicted FVC divided by the percentage of predicted 
DCLO, the presence of telangiectasia, the presence of anti-centromere antibodies, the serum 
level of N-terminal pro-BNP, the serum level of urate, and whether there are signs of right-axis 
deviation on ECG. The total risk score can be calculated at: http://detect-pah.com. In step 2, 
the step 1 prediction score and two echocardiographic variables, right atrium enlargement 
and TRJ velocity, determine which patients should subsequently be referred for an RHC. The 
results from the DETECT study showed that the algorithm recommended RHC in 62% of 
patients (referral rate) and missed 4% of PAH patients (false negatives). By comparison, when 
the European Society of Cardiology/European Respiratory Society guidelines were applied to 
these patients, 29% of diagnoses were missed while requiring an RHC referral rate of 40% [29].
Figure 2. Recommendations when to perform a right-heart catheterization are shown. FVC: forced vital capacity, 
DCLO: diffusion capacity for carbon monoxide, NT-pro-BNP N-terminal pro brain natriuretic peptide, TRJ: tricuspid 
regurgitation jet, RA: right atrium, RV: right ventricle, PH: pulmonary hypertension, and RHC: right heart catheterization.
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For those patients with systemic sclerosis with a disease duration of more than 3 years and a 
pulmonary diffusion capacity for carbon monoxide (DCLO) above 60% of the predicted value, 
a yearly screening for PH is recommended by means of a pulmonary function test, including 
DCLO and, serum level of N-terminal pro-BNP [28–31]. Figure 4 displays the flow chart and 
recommends an echocardiography when there is a decline of more than 20% in DCLO within 
1 year, a FVC/DCLO ratio below 1.6, or a N-terminal pro-BNP serum level more than twice 
above the upper limit of normal. Depending on the results of the echocardiography, an RHC is 
Figure 3. DETECT algorithm in patients with systemic sclerosis with more than 3 years of disease duration and 
DCLO<60%.
Figure 4. A flow chart for screening PH in patients with systemic sclerosis with more than 3 years of disease duration 
and DCLO > 60%.
Pulmonary Hypertension in Systemic Sclerosis
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recommended (Figure 2B). When there are signs of cardiac failure without a known etiology, 
signs of pericardial effusion, or a strong suspicion of PH (despite a normal or slightly ele-
vated N-terminal pro-BNP and DCLO above 60% of predicted value), an echocardiography 
is recommended.
3. Treatment of pulmonary hypertension
The treatment of PH in patients with systemic sclerosis is a complex strategy which consists 
of a thorough evaluation of the severity of PH and the subsequent response to treatment. The 
treatment should be done by a team of experts in the field of rheumatology, cardiology, and 
pulmonary medicine and, in most countries, is restricted to highly specialized hospitals. Before 
treatment can be initiated, the NYHA/WHO group of PH should be defined in each patient. 
Vasoactive treatment is only indicated and reimbursed for NYHA/WHO group 1, PAH and 
NYHA/WHO group 4, and chronic thromboembolic pulmonary hypertension. The treatment 
strategy for PH can be divided into three main steps [16]. The first consists of general measures, 
supportive therapy, and referral to a specialized center. The second step includes the initiation 
of drugs approved for the treatment of PH. The final third step is related to the response to the 
initial treatment strategy and, in case of an inadequate response, the role of drug-combination 
therapy and lung transplantation. To note, the initial drug therapy, whether drug mono-therapy 
or drug-combination therapy for PH, depends on the NYHA/WHO functional class (Table 2). 
In patients with a severe disease (WHO functional class ≥ III), there is a high-estimated 1-year 
mortality and consequently the urge for a more aggressive treatment strategy [27].
In the first treatment step, general measures should be discussed with patients with systemic 
sclerosis–associated PH. This includes the encouragement to be physically active within symp-
tom limits and to avoid excessive physical activity that leads to distressing symptoms [32, 
33]. The exercise training programs should be conducted in centers which have experience 
in the care for PH patients. Since PH patients are at risk to develop pneumonia [34], vaccina-
tion against influenza and pneumococcal pneumonia is recommended. Patients should also 
be instructed that when (elective) surgery is necessary, the anesthesiologist is familiar with 
their PH and when possible local anesthesia or an epidural is preferable [35]. Furthermore, 
pregnancy should be avoided. As PH has a severe impact on daily living and may be life threat-
ening, psychological, social, and emotional support is advocated [36]. One of the recommenda-
tions for supportive therapy for PH in patients with systemic sclerosis is the use of diuretics 
in those patients who show signs of right heart failure and fluid retention [37]. Although there 
are no RCTs on the use of diuretics in PH, clinical experience of experts show clear benefits. 
Continuous long-term oxygen (O
2
) therapy is only recommended in PH patients when arte-
rial blood O
2
 pressure is consistently below 8 kPa [38], as in patients with chronic obstructive 
pulmonary disease (COPD). There are no scientific data which suggest that long-term oxygen 
therapy is beneficial. The evidence for the use of oral anticoagulants in patients with PH is not 
proven [39] despite the high prevalence of vascular thrombotic events [40] and risk factors such 
as heart failure, immobility, and coagulation abnormalities [41]. The final recommendation for 
supportive therapy is iron substitution in those patients with systemic sclerosis–associated PH 
with known iron deficiencies [42].
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The second step in the treatment of PH consists of treatment of the underlying cause or initi-
ating vasoactive therapy if appropriate. In patients with NYHA/WHO group 2 PH, it is due 
to left heart disease, optimization of cardiac function, and/or valvular disease. In patients 
with PH associated with lung disease, NYHA/WHO group 3, specific treatment of the cause 
of this disease is mandatory. PH treatment includes the initiation of drug therapy accord-
ing to the evidence-based treatment algorithm [16]. In 2012, Nickel et al. [43] showed that 
goal-orientated therapy, a treatment strategy that uses known prognostic indicators (NYHA/
WHO functional class, N-terminal pro-BNP, cardiac index) as treatment targets resulted in 
better prognosis in the patients achieving these goals. Changes in these established prognos-
tic indicators during the course of the disease provide important prognostic information. 
In contrast to other causes of PH, such as idiopathic PAH, there is no long-term favorable 
response to calcium-channel blockers in patients with systemic sclerosis associated-PH [44]. 
The three pathogenetic pathways targeted by drug therapy in patients with systemic sclero-
sis–associated PH are the endothelin pathway, the nitric oxide pathway, and the prostacyclin 
pathway as depicted in Figure 5 [45].
Endothelin (ET-1) is a peptide produced by endothelial cells which have vasoconstrictive 
and proliferative effects and is a mediator of vascular hypertrophy and fibrosis. In patients 
with PH, ET-1 concentrations are elevated and correlated with indices of disease severity 
[46]. There are two distinct receptor isoforms in the pulmonary vascular smooth muscle cells, 
the so-called endothelin receptor type A and B. Blocking of these ET-1 receptors by endo-
thelin receptor antagonists (ERAs) has shown to exert beneficial effects on WHO functional 
class, improved hemodynamics, and an increased time to clinical worsening [47–50]. There 
are no head-to-head studies comparing the three available ERAs (ambrisentan, bosentan, and 
Figure 5. Targeted medical therapy for pulmonary arterial hypertension based on the endothelin pathway, nitric oxide 
pathway, and prostacyclin pathway. Adapted from Humbert et al. [45]. ERA: endothelin receptor antagonist, PDE
5
-I: 
phosphodiesterase type 5 inhibitor, NO: nitric oxide, and PGI
2
: prostacyclin derivates.
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macitentan), and they are considered to have similar efficacy. The most serious side effect of 
ambricentan and bosentan, but not Macitentan, is liver toxicity which was found to be dose 
dependent and reversible. Monthly liver function assessment is therefore recommended.
The second pathway targeted by drug therapy in patients with systemic sclerosis asso-
ciated-PH is the nitric oxide (NO) pathway. NO stimulates guanylate cyclase in vascular 
smooth muscle cells to convert guanosine triphosphate (GTP) to cyclic guanosine mono-
phosphate (cGMP), which ultimately decreases intracellular calcium levels and thereby 
promotes vascular smooth muscle relaxation [51, 52]. As such, NO is considered a power-
ful vasodilator. In the pulmonary vasculature, phosphodiesterase type 5 (PDE
5
) degrades 
cGMP. As a consequence, inhibition of PDE
5
 by PDE
5
 inhibitors (PDE
5
-i) results in vasodila-
tion through the NO/cGMP pathway. At the moment, there are two registered PDE
5
-i for 
PH called sildenafil and tadalafil. Both sildenafil [53, 54] and tadalafil [55] have shown ben-
eficial effects such as an improved exercise capacity and prolonged time to clinical worsen-
ing in RCTs after 12 weeks of treatment. The soluble guanylate cyclase stimulator, called 
riociguat, enhances cGMP production and has also shown favorable results on exercise 
capacity, hemodynamics, NYHA/WHO functional class, and, time to clinical worsening in 
patients with PH [56].
The final possible targeted pathway in the treatment of PH is the prostacyclin pathway. 
Prostacyclin is mainly produced by vascular endothelial cells and induces vasodilation of the 
vascular bed [57] and is a powerful inhibitor of platelet aggregation [58]. Prostacyclin exerts 
its effects by ultimately increasing the production of intracellular cyclic adenosine monophos-
phate (cAMP). Unfortunately, it has a very short half-life time of about 3 min. The introduc-
tion of stable analogues of prostacyclin with different pharmacokinetic properties but similar 
pharmacodynamic properties extended the clinical use of prostacyclins. Epoprostenol, a syn-
thetic prostacyclin, has a short half-life time and requires cooling and continuous admin-
istration by means of an infusion pump and tunneled venous catheter. In an unblinded 
Randomized Controlled Trial (RCT), the effects of epoprostenol on 111 patients with PH sec-
ondary to the scleroderma spectrum of disease showed an improvement in exercise capacity, 
cardiopulmonary hemodynamics, and a decrease in mPAP [59]. Serious side effects such as 
venous catheter infections, sepsis, and pump malfunction have been described and may lead 
to death. Iloprost is a chemically more stable prostacyclin analogue and can be administered 
intravenously or via inhalation. Both inhaled iloprost [60] and intravenous iloprost [61] have 
shown to improve exercise capacity and clinical symptoms. Treprostenil is an analogue of 
epoprostenol with sufficient chemical stability to be administered without cooling. Both the 
subcutaneous administration and inhalation of treprostenil have shown beneficial effects in 
patients with PH [62, 63]. Recently, the first oral selective IP-prostacyclin receptor agonist 
selexipag was approved. In an event-driven study in 1156 patients, a 40% reduction of mortal-
ity and PH-associated complications were found in the selexipag-treated patients [64].
Figure 6 shows the current treatment algorithm for systemic sclerosis associated-PH [16]. 
Initial drug therapy, whether drug monotherapy or drug-combination therapy for PH, 
depends on the NYHA/WHO functional class combined with determinants of a worse prog-
nosis such as clinical signs of heart failure, syncope, N-terminal pro-BNP plasma levels above 
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300ng/l,  echocardiographic signs of right atrial enlargement, 6-min walking distance, and/or 
low physical fitness levels (VO
2, 
peak oxygen consumption < 15 ml/min/kg).
3.1. Combination therapy
When initial drug monotherapy in PH patients with WHO functional class I–II fails or 
when patients with systemic sclerosis associated-PH at first diagnoses are already in WHO 
functional class II–IV, combination therapy can be applied. Because of the three possible 
targeted pathways (ET-1-, NO-, and prostacyclin pathway), this was thought to be an attrac-
tive option [65]. Combination therapy can be applied sequentially or upfront. Sequential 
therapy was the most widely used strategy; in case of an inadequate response to mono-
therapy, a second and subsequently a third drug can be added. Several trials have been 
conducted which evaluated the efficacy of drug combination therapy compared to mono-
therapy. A recent meta-analysis on 15 RCTs, with combination of PAH-specific therapies 
(upfront and sequential add-ons) compared with PAH-specific monotherapy, showed a risk 
reduction for clinical worsening of 17 versus 28%, respectively [66]. A similar outcome was 
observed by a meta-analyses from Fox et al. [67] on 18 RCTs. Combination therapy was 
associated with a reduction in non-fatal end points, an improved 6-min walking distance, 
improved functional class, and pulmonary hemodynamics. So far, the strongest scientific 
evidence has been found for the combination therapy of ambrisentan and tadalafil in PH 
Figure 6. A treatment algorithm for systemic sclerosis associated-PH. ERA: endothelin receptor antagonist, PDE
5
-I: 
phosphodiesterase type 5 inhibitor, and PGI
2
: prostacyclin derivates.
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patients with NYHA/WHO functional class II and III [68]. Only recently, the effects of initial 
triple upfront combination therapy in patients diagnosed with PH has been evaluated [69]. 
Nineteen newly diagnosed NYHA/WHO functional class III/IV PAH patients initiated on 
upfront triple combination therapy (intravenous epoprostenol, bosentan, and sildenafil) 
were collected retrospectively. After 4 months' triple combination therapy, 18 patients sig-
nificantly improved their 6-min walking distance and hemodynamics. Seventeen patients 
had improved to NYHA/WHO functional class I or II but most striking was the overall 
estimated survival of 100% after 1, 2, and 3 years [69].
3.2. Lung transplantation
When patients decline despite aggressive drug therapy and other interventions, lung trans-
plantation can be considered. The first lung transplantation for pulmonary vascular disease 
was performed in 1982 at Stanford University by Dr. Reitz and colleagues [70]. The timing 
of transplantation is crucial and depends on several factors, including the cause of PH, stage 
of the disease, co-morbidities and suitability for operation, possible alternative treatments, 
and of course, availability of donors. Patients with systemic sclerosis were initially often 
denied transplantation because of concerns about the short- and long-term outcomes related 
to the extra-pulmonary manifestations of systemic sclerosis [71]. A systematic review per-
formed by Khan et al. [72] addressed this issue and evaluated the survival of systemic scle-
rosis patients after lung transplantation. He identified seven observational studies reporting 
the results of approximately 185 patients with systemic sclerosis who underwent single-
lung, double-lung, or heart-lung transplantation. The indication for lung transplantation 
was both ILD and/or PAH related. The results showed that post-transplantation survival 
ranged 69–91% at 30 days, 69–85% at 6 months, 59–93% at 1 year, 49–80% at 2 years, and 
46–79% at 3 years. He concluded that the short-term and intermediate-term survival after 
lung transplantation were similar to patients with idiopathic forms of PAH and other causes 
of ILD requiring lung transplantation. So nowadays, systemic sclerosis is a widely accepted 
diagnosis for the potential necessary lung transplantation. Remarkable was the consider-
able variability in survival estimates. This is probably due to different selection criteria of 
patients and may also be related to survival differences across systemic sclerosis patients 
with PAH, ILD, or a combination of PAH and ILD. Future work should aim to prospectively 
study adults with systemic sclerosis as they are evaluated for lung transplantation in order 
to identify potentially modifiable risk factors that can improve transplant outcomes in this 
population [73].
Author details
Fleur Poelkens, Madelon C. Vonk and Annelies E. van Ede*
*Address all correspondence to: annelies.vanede@radboudumc.nl
Radboud University Medical Center, Nijmegen, the Netherlands
Systemic Sclerosis14
References
[1] Hachulla E, Carpentier P, Gressin V, Diot E, Allanore Y, Sibilia J, et al. Risk factors for 
death and the 3-year survival of patients with systemic sclerosis: The French ItinerAIR-
Sclerodermie study. Rheumatology. 2009;48(3):304-308
[2] Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, et al. The three-
year incidence of pulmonary arterial hypertension associated with systemic sclerosis 
in a multicenter nationwide longitudinal study in France. Arthritis and Rheumatism. 
2009;60(6):1831-1839
[3] Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pul-
monary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 
5 studies. The Journal of Rheumatology. 2010;37(11):2290-2298
[4] Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic scle-
rosis: An analysis of 17 patients. British Journal of Rheumatology. 1996;35(10):989-993
[5] Lefevre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al. Survival 
and prognostic factors in systemic sclerosis-associated pulmonary hypertension: A sys-
tematic review and meta-analysis. Arthritis and Rheumatism. 2013;65(9):2412-2423
[6] Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics 
and survival in patients with pulmonary arterial hypertension related to systemic scle-
rosis. Chest. 2003;123(2):344-350
[7] Hachulla E, Launay D, Mouthon L, Sitbon O, Berezne A, Guillevin L, et al. Is pulmo-
nary arterial hypertension really a late complication of systemic sclerosis? Chest. 
2009;136(5):1211-1219
[8] MacGregor AJ, Canavan R, Knight C, Denton CP, Davar J, Coghlan J, et al. Pulmonary 
hypertension in systemic sclerosis: Risk factors for progression and consequences for 
survival. Rheumatology. 2001;40(4):453-459
[9] Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and 
outcome in systemic sclerosis associated pulmonary arterial hypertension: Application 
of a registry approach. Annals of the Rheumatic Diseases. 2003;62(11):1088-1093
[10] Nihtyanova SI, Tang EC, Coghlan JG, Wells AU, Black CM, Denton CP. Improved sur-
vival in systemic sclerosis is associated with better ascertainment of internal organ 
disease: A retrospective cohort study. QJM: Monthly Journal of the Association of 
Physicians. 2010;103(2):109-115
[11] Hatano S, Strasser T. Primary Pulmonary Hypertension. Report on a WHO Meeting. 
Geneva: World Health Organization; 1973
[12] Fishman AP. Clinical classification of pulmonary hypertension. Clinics in Chest Medicine. 
2001;22(3):385-391
Pulmonary Hypertension in Systemic Sclerosis
http://dx.doi.org/10.5772/intechopen.68535
15
[13] Galie N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clini-
cal trials and evidence-based treatment algorithm in pulmonary arterial hypertension. 
Journal of the American College of Cardiology. 2004;43(12 Suppl S):81S–88S
[14] Galie N, Simonneau G. The Fifth World Symposium on Pulmonary Hypertension. 
Journal of the American College of Cardiology. 2013;62(25 Suppl):D1–D3
[15] Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. 
Updated clinical classification of pulmonary hypertension. Journal of the American 
College of Cardiology. 2013;62(25 Suppl):D34–D41
[16] Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS 
Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task 
Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European 
Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: 
Association for European Paediatric and Congenital Cardiology (AEPC), International 
Society for Heart and Lung Transplantation (ISHLT). European Heart Journal. 2016; 
37(1):67-119
[17] Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, et al. 
Diagnosis and assessment of pulmonary arterial hypertension. Journal of the American 
College of Cardiology. 2009;54(1 Suppl):S55–S66
[18] Valerio CJ, Schreiber BE, Handler CE, Denton CP, Coghlan JG. Borderline mean pul-
monary artery pressure in patients with systemic sclerosis: Transpulmonary gradi-
ent predicts risk of developing pulmonary hypertension. Arthritis and Rheumatism. 
2013;65(4):1074-1084
[19] Launay D, Sitbon O, Hachulla E, Mouthon L, Gressin V, Rottat L, et al. Survival in sys-
temic sclerosis-associated pulmonary arterial hypertension in the modern management 
era. Annals of the Rheumatic Diseases. 2013;72(12):1940-1946
[20] Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, et al. 
Survival in pulmonary hypertension associated with the scleroderma spectrum of dis-
eases: Impact of interstitial lung disease. Arthritis and Rheumatism. 2009;60(2):569-577
[21] Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tis-
sue disease-associated pulmonary arterial hypertension in the modern treatment era. 
American Journal of Respiratory and Critical Care Medicine. 2009;179(2):151-157
[22] Dorfmuller P, Humbert M, Perros F, Sanchez O, Simonneau G, Muller KM, et al. Fibrous 
remodeling of the pulmonary venous system in pulmonary arterial hypertension associ-
ated with connective tissue diseases. Human Pathology. 2007;38(6):893-902
[23] Gunther S, Jais X, Maitre S, Berezne A, Dorfmuller P, Seferian A, et al. Computed tomog-
raphy findings of pulmonary venoocclusive disease in scleroderma patients presenting 
with precapillary pulmonary hypertension. Arthritis and Rheumatism. 2012;64(9): 
2995-3005
Systemic Sclerosis16
[24] Kahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheuma-
tology. 2006;45(Suppl 4):iv14–iv17
[25] Fernandez-Codina A, Simeon-Aznar CP, Pinal-Fernandez I, Rodriguez-Palomares J, Pizzi 
MN, Hidalgo CE, et al. Cardiac involvement in systemic sclerosis: Differences between 
clinical subsets and influence on survival. Rheumatology International. 2017;37(1):75-84
[26] Humbert M, Sitbon O, Yaici A, Montani D, O’Callaghan DS, Jais X, et al. Survival in 
incident and prevalent cohorts of patients with pulmonary arterial hypertension. The 
European Respiratory Journal. 2010;36(3):549-555
[27] Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, et al. Survival and 
predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: 
Outcomes from the pulmonary hypertension assessment and recognition of outcomes in 
scleroderma registry. Arthritis Care & Research. 2014;66(3):489-495
[28] Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE, et al. Recommendations 
for screening and detection of connective tissue disease-associated pulmonary arterial 
hypertension. Arthritis and Rheumatism. 2013;65(12):3194-3201
[29] Coghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D, et al. Evidence-
based detection of pulmonary arterial hypertension in systemic sclerosis: The DETECT 
study. Annals of the Rheumatic Diseases. 2014;73(7):1340-1349
[30] Schwaiger JP, Khanna D, Gerry Coghlan J. Screening patients with scleroderma for 
pulmonary arterial hypertension and implications for other at-risk populations. 
European Respiratory Review: An Official Journal of the European Respiratory Society. 
2013;22(130):515-525
[31] Thakkar V, Stevens W, Prior D, Youssef P, Liew D, Gabbay E, et al. The inclusion of 
N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic 
sclerosis-related pulmonary arterial hypertension: A cohort study. Arthritis Research & 
Therapy. 2013;15(6):R193
[32] Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines 
for the diagnosis and treatment of pulmonary hypertension: The Task Force for the 
Diagnosis and Treatment of Pulmonary Hypertension of the European Society of 
Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the 
International Society of Heart and Lung Transplantation (ISHLT). European Heart 
Journal. 2009;30(20):2493-2537
[33] Grunig E, Maier F, Ehlken N, Fischer C, Lichtblau M, Blank N, et al. Exercise training 
in pulmonary arterial hypertension associated with connective tissue diseases. Arthritis 
Research & Therapy. 2012;14(3):R148
[34] Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary 
pulmonary hypertension. A national prospective study. Annals of Internal Medicine. 
1987;107(2):216-223
Pulmonary Hypertension in Systemic Sclerosis
http://dx.doi.org/10.5772/intechopen.68535
17
[35] Meyer S, McLaughlin VV, Seyfarth HJ, Bull TM, Vizza CD, Gomberg-Maitland M, et al. 
Outcomes of noncardiac, nonobstetric surgery in patients with PAH: An international 
prospective survey. The European Respiratory Journal. 2013;41(6):1302-1307
[36] Guillevin L, Armstrong I, Aldrighetti R, Howard LS, Ryftenius H, Fischer A, et al. 
Understanding the impact of pulmonary arterial hypertension on patients’ and carers’ 
lives. European Respiratory Review: An Official Journal of the European Respiratory 
Society. 2013;22(130):535-542
[37] Cohn JN. Optimal diuretic therapy for heart failure. The American Journal of Medicine. 
2001;111(7):577
[38] Sandoval J, Aguirre JS, Pulido T, Martinez-Guerra ML, Santos E, Alvarado P, et al. 
Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. American 
Journal of Respiratory and Critical Care Medicine. 2001;164(9):1682-1687
[39] Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, et al. Anticoagulation 
and survival in pulmonary arterial hypertension: Results from the Comparative, 
Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension 
(COMPERA). Circulation. 2014;129(1):57-65
[40] Schoenfeld SR, Choi HK, Sayre EC, Avina-Zubieta JA. Risk of pulmonary embolism 
and deep venous thrombosis in systemic sclerosis: A general population-based study. 
Arthritis Care & Research. 2016;68(2):246-253
[41] Herve P, Humbert M, Sitbon O, Parent F, Nunes H, Legal C, et al. Pathobiology of pul-
monary hypertension. The role of platelets and thrombosis. Clinics in Chest Medicine. 
2001;22(3):451-458
[42] Ruiter G, Lanser IJ, de Man FS, van der Laarse WJ, Wharton J, Wilkins MR, et al. Iron 
deficiency in systemic sclerosis patients with and without pulmonary hypertension. 
Rheumatology. 2014;53(2):285-292
[43] Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, et al. The prog-
nostic impact of follow-up assessments in patients with idiopathic pulmonary arterial 
hypertension. The European Respiratory Journal. 2012;39(3):589-596
[44] Montani D, Savale L, Natali D, Jais X, Herve P, Garcia G, et al. Long-term response to 
calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. European 
Heart Journal. 2010;31(15):1898-1907
[45] Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. 
The New England Journal of Medicine. 2004;351(14):1425-1436
[46] Montani D, Souza R, Binkert C, Fischli W, Simonneau G, Clozel M, et al. Endothelin-1/
endothelin-3 ratio: A potential prognostic factor of pulmonary arterial hypertension. 
Chest. 2007;131(1):101-108
[47] Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for 
the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary 
Systemic Sclerosis18
arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy 
(ARIES) study 1 and 2. Circulation. 2008;117(23):3010-3019
[48] Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients 
with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY 
study): A double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093-2100
[49] Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of 
the dual endothelin-receptor antagonist bosentan in patients with pulmonary hyperten-
sion: A randomised placebo-controlled study. Lancet. 2001;358(9288):1119-1123
[50] Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, et al. Macitentan 
and morbidity and mortality in pulmonary arterial hypertension. The New England 
Journal of Medicine. 2013;369(9):809-818
[51] Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, et al. Guanylyl 
cyclases and signaling by cyclic GMP. Pharmacological Reviews. 2000;52(3):375-414
[52] Pfeifer A, Ruth P, Dostmann W, Sausbier M, Klatt P, Hofmann F. Structure and func-
tion of cGMP-dependent protein kinases. Reviews of Physiology, Biochemistry and 
Pharmacology. 1999;135:105-149
[53] Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary 
pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover 
study. Journal of the American College of Cardiology. 2004;43(7):1149-1153
[54] Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-con-
trolled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy 
in severe pulmonary artery hypertension. American Heart Journal. 2006;151(4):851 
e1-851 e5
[55] Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil 
therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894-2903
[56] Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat 
for the treatment of pulmonary arterial hypertension. The New England Journal of 
Medicine. 2013;369(4):330-340
[57] Rubin LJ, Groves BM, Reeves JT, Frosolono M, Handel F, Cato AE. Prostacyclin-induced 
acute pulmonary vasodilation in primary pulmonary hypertension. Circulation. 
1982;66(2):334-338
[58] Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between plate-
lets and blood-vessel walls. The New England Journal of Medicine. 1979;300(20):1142– 
1147
[59] Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al. 
Continuous intravenous epoprostenol for pulmonary hypertension due to the sclero-
derma spectrum of disease. A randomized, controlled trial. Annals of Internal Medicine. 
2000;132(6):425-434
Pulmonary Hypertension in Systemic Sclerosis
http://dx.doi.org/10.5772/intechopen.68535
19
[60] Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled 
iloprost for severe pulmonary hypertension. The New England Journal of Medicine. 
2002;347(5):322-329
[61] Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long-term intravenous 
prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hyperten-
sion. Heart. 1998;80(2):151-155
[62] Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcu-
taneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary 
arterial hypertension: A double-blind, randomized, placebo-controlled trial. American 
Journal of Respiratory and Critical Care Medicine. 2002;165(6):800-804
[63] McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. 
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: 
A randomized controlled clinical trial. Journal of the American College of Cardiology. 
2010;55(18):1915-1922
[64] Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the treat-
ment of pulmonary arterial hypertension. The New England Journal of Medicine. 2015; 
373(26):2522-2533
[65] Benza RL, Park MH, Keogh A, Girgis RE. Management of pulmonary arterial hyper-
tension with a focus on combination therapies. The Journal of Heart and Lung 
Transplantation: The Official Publication of the International Society for Heart Transplan-
tation. 2007;26(5):437-446
[66] Lajoie AC, Lauziere G, Lega JC, Lacasse Y, Martin S, Simard S, et al. Combination ther-
apy versus monotherapy for pulmonary arterial hypertension: A meta-analysis. The 
Lancet Respiratory Medicine. 2016;4(4):291-305
[67] Fox BD, Shtraichman O, Langleben D, Shimony A, Kramer MR. Combination therapy for 
pulmonary arterial hypertension: A systematic review and meta-analysis. The Canadian 
Journal of Cardiology. 2016
[68] Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial 
use of ambrisentan plus tadalafil in pulmonary arterial hypertension. The New England 
Journal of Medicine. 2015;373(9):834-844
[69] Sitbon O, Jais X, Savale L, Cottin V, Bergot E, Macari EA, et al. Upfront triple combination 
therapy in pulmonary arterial hypertension: A pilot study. The European Respiratory 
Journal. 2014;43(6):1691-1697
[70] Reitz BA, Wallwork JL, Hunt SA, Pennock JL, Billingham ME, Oyer PE, et al. Heart-lung 
transplantation: Successful therapy for patients with pulmonary vascular disease. The 
New England Journal of Medicine. 1982;306(10):557-564
[71] Massad MG, Powell CR, Kpodonu J, Tshibaka C, Hanhan Z, Snow NJ, et al. Outcomes 
of lung transplantation in patients with scleroderma. World Journal of Surgery. 
2005;29(11):1510-1515
Systemic Sclerosis20
[72] Khan IY, Singer LG, de Perrot M, Granton JT, Keshavjee S, Chau C, et al. Survival after 
lung transplantation in systemic sclerosis. A systematic review. Respiratory Medicine. 
2013;107(12):2081-2087
[73] Bernstein EJ, Peterson ER, Sell JL, D’Ovidio F, Arcasoy SM, Bathon JM, et al. Survival 
of adults with systemic sclerosis following lung transplantation: A nationwide cohort 
study. Arthritis & Rheumatology. 2015;67(5):1314-1322
Pulmonary Hypertension in Systemic Sclerosis
http://dx.doi.org/10.5772/intechopen.68535
21

